Literature DB >> 18261250

Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days.

Eszter Kirilly1, Eszter Molnar, Brigitta Balogh, Sandor Kantor, Stefan R Hansson, Miklos Palkovits, Gyorgy Bagdy.   

Abstract

The recreational drug ecstasy [3,4-methylenedioxymethamphetamine (MDMA)], has been found to selectively damage brain serotonin neurons in experimental animals, and probably in human MDMA users, but detailed morphometric analyses and parallel functional measures during damage and recovery are missing. Since there is evidence that serotonin regulates sleep, we have compared serotonergic markers parallel with detailed analysis of sleep patterns at three time-points within 180 d after a single dose of 15 mg/kg MDMA in male Dark Agouti rats. At 7 d and 21 d after MDMA treatment, significant(30-40%), widespread reductions in serotonin transporter (5-HTT) density were detected in the cerebral cortex, hippocampus, most parts of the hypothalamus, and some of the brainstem nuclei. With the exception of the hippocampus, general recovery was observed in the brain 180 d after treatment. Transient increases followed by decreases were detected in 5-HTT mRNA expression of dorsal and median raphe nuclei at 7 d and 21 d after the treatment. Significant reductions in rapid eye movement (REM) sleep latency, increases in delta power spectra in non-rapid eye movement sleep and increased fragmentation of sleep were also detected, but all these alterations disappeared by the 180th day. The present data provide evidence for long-term, albeit, except for the hippocampus, transient changes in the terminal and cellular regions of the serotonergic system after this drug. Reduced REM latency and increased sleep fragmentation are the most characteristic alterations of sleep consistently described in depression using EEG sleep polygraphy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18261250     DOI: 10.1017/S1461145708008535

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  11 in total

1.  Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls.

Authors:  Robin L Carhart-Harris; David J Nutt; Marcus R Munafo; David M Christmas; Sue J Wilson
Journal:  Psychopharmacology (Berl)       Date:  2009-07-08       Impact factor: 4.530

2.  Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat.

Authors:  Csaba Adori; Péter Low; Rómeó D Andó; Lise Gutknecht; Dorottya Pap; Ferencné Truszka; József Takács; Gábor G Kovács; Klaus-Peter Lesch; György Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2010-10-30       Impact factor: 4.530

3.  Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.

Authors:  Norbert Gyongyosi; Brigitta Balogh; Zita Katai; Eszter Molnar; Rudolf Laufer; Kornelia Tekes; Gyorgy Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2010-01-06       Impact factor: 3.575

4.  Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances.

Authors:  Kirk J Brower; Brian E Perron
Journal:  Med Hypotheses       Date:  2009-11-11       Impact factor: 1.538

5.  3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity.

Authors:  Elisabet Cuyas; Patricia Robledo; Nieves Pizarro; Magí Farré; Elena Puerta; Norberto Aguirre; Rafael de la Torre
Journal:  Neurotox Res       Date:  2013-08-15       Impact factor: 3.911

6.  Procedural and declarative memory task performance, and the memory consolidation function of sleep, in recent and abstinent ecstasy/MDMA users.

Authors:  Mark Blagrove; Jennifer Seddon; Sophie George; Andrew C Parrott; Robert Stickgold; Matthew P Walker; Katy A Jones; Michael J Morgan
Journal:  J Psychopharmacol       Date:  2010-07-08       Impact factor: 4.153

7.  The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis.

Authors:  Dominik K Biezonski; Jerrold S Meyer
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

8.  The rostromedial tegmental nucleus is essential for non-rapid eye movement sleep.

Authors:  Su-Rong Yang; Zhen-Zhen Hu; Yan-Jia Luo; Ya-Nan Zhao; Huan-Xin Sun; Dou Yin; Chen-Yao Wang; Yu-Dong Yan; Dian-Ru Wang; Xiang-Shan Yuan; Chen-Bo Ye; Wei Guo; Wei-Min Qu; Yoan Cherasse; Michael Lazarus; Yu-Qiang Ding; Zhi-Li Huang
Journal:  PLoS Biol       Date:  2018-04-13       Impact factor: 8.029

9.  Gene expression analysis indicates CB1 receptor upregulation in the hippocampus and neurotoxic effects in the frontal cortex 3 weeks after single-dose MDMA administration in Dark Agouti rats.

Authors:  Peter Petschner; Viola Tamasi; Csaba Adori; Eszter Kirilly; Romeo D Ando; Laszlo Tothfalusi; Gyorgy Bagdy
Journal:  BMC Genomics       Date:  2013-12-30       Impact factor: 3.969

10.  Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in Dark Agouti rats.

Authors:  Peter Petschner; Viola Tamasi; Csaba Adori; Eszter Kirilly; Romeo D Ando; Laszlo Tothfalusi; Gyorgy Bagdy
Journal:  BMC Genomics       Date:  2018-08-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.